Inmed Pharmaceuticals Inc. · NASDAQ:INM
Inmed Pharmaceuticals — Investor Presentation (September 2023)
23 slides from Inmed Pharmaceuticals's investor presentation, September 2023
Slide 1: Corporate Presentation
Corporate Presentation September 2023 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: A Pure-Play Rare Cannabinoid Company
A Pure-Play Rare Cannabinoid Company RARE CANNABINOID EXPERTISE ACROSS SEVERAL AREAS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of • Screening of therapeutic • Chemical and • B2B supplier to health pharmaceutical programs candidates biosynthesis expertise and wellness indu
Slide 4: Cannabinoid Drug Development Programs
Cannabinoid Drug Development Programs
Slide 5: Pharmaceutical Development of Rare Cannabinoids
Pharmaceutical Development of Rare Cannabinoids HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 NATURALLY-OCCURRING CANNABINOIDS -Phase 2 - Study completed INM-755 CBN -Showed a positive indication of enhanced anti-itch activity versus control cream Seeking Strategic Partnerships Epidermolysis bullo
Slide 6: Phase 2 Clinical Trial: INM-755 Cannabinol (CBN) Cream
Phase 2 Clinical Trial: INM-755 Cannabinol (CBN) Cream Purpose of Trial Patient Enrollment Evaluate the safety of INM-755 CBN cream and obtain preliminary evidence of efficacy in treating symptoms and • Trial enrolled 19 patients wound healing in patients with EB. • 18 remaining patients whose data
Slide 7: Phase 2 Results: INM-755 Cannabinol (CBN) Cream
Phase 2 Results: INM-755 Cannabinol (CBN) Cream Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A positive indication of enhanced anti-itch activity clinically meaningful amount in 12 patients (66.7%), of whom: for INM-755 cream versus the co
Slide 8: Glaucoma – Leading Cause of Blindness for Age 60+
Glaucoma – Leading Cause of Blindness for Age 60+ CURRENT MEDICATIONS WORK TO REDUCE INTRAOCULAR PRESSURE Unmet medical need Glaucoma market Current treatments do not proactively protect the eye or reverse the progression of glaucoma and only slow the progression of Second leading cause of blindness
Slide 9: INM-088: Potential Roles for CBN in Glaucoma
INM-088: Potential Roles for CBN in Glaucoma CANNABINOL DEMONSTRATES REDUCTION OF IOP AND NEUROPROTECTIVE EFFECTS Front of eye Back of eye IOP reduction Neuroprotection Target Effects of CBN Retina • Direct neuroprotection for the retina and optic nerve, independent of intraocular Pressure pressure
Slide 10: Neurodegenerative Diseases – A Gap in Treatment
Neurodegenerative Diseases – A Gap in Treatment CANNABINOIDS SHOWN TO INHIBIT NEURODEGENERATIVE DISEASE PROGRESSION IN PRECLINICAL MODELS Unmet medical need Medications to treat Alzheimer's may slow the rate of cognitive Milestones decline but none have been shown to halt nor reverse its PCT patent
Slide 11: Cannabinoids Can Act on Receptors Expressed in the Brain
Cannabinoids Can Act on Receptors Expressed in the Brain CANNABINOIDS ARE HIGHLY LIPOPHILIC Examples of receptors expressed in the brain CB1 Receptors concentrated in the brain and central nervous system but are also present in some nerves and organs GPR6 Receptors mainly expressed in the brain, par
Slide 12: Potential to enhance neuronal function
Potential to enhance neuronal function SELECTED CANNABINOID ANALOGS DEMONSTRATES NEUROPROTECTIVE EFFECTS Cannabinoid analogs increased neurite outgrowth The selected cannabinoid analogs demonstrated neuroprotecti ve effects and enhanced neuronal function Differentiated Differentiated neuronal cells
Slide 13: A Diverse Patent Portfolio
A Diverse Patent Portfolio 13 PATENT FAMILIES – NCEs/Formulations, Manufacturing Methods, Methods of Use, NCEs Manufacturing Methods of use 2 patent families filed 7 patent families filed 4 patent families filed • 21 international pending • 2 granted • 2 granted • 29 international pending • 22 inter
Slide 14: Rare Cannabinoid Manufacturing
Rare Cannabinoid Manufacturing
Slide 15: Unparalleled Cannabinoid Manufacturing Expertise
Unparalleled Cannabinoid Manufacturing Expertise NO OTHER COMPANY HAS THE SAME BREADTH AND DEPTH IN CANNABINOID MANUFACTURING Manufacturing Approaches Biosynthesis Chemical Synthesis • Able to select the most effective manufacturing method depending on the target cannabinoid • Ability to scale to me
Slide 16: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONSISTENCY C O S T- E F F E C T I V E N E S S High quality, bioidentical rare cannabinoids with exceptiona
Slide 17: BayMedica – Revenue Trending Positively
BayMedica – Revenue Trending Positively INCREASED DEMAND FOR BAYMEDICA’S BIOIDENTICAL RARE CANNABINOIDS Fiscal 2023 Revenue Growth US$ $2.3M* 2500000 • Surpassed $2.3M sales in Q4 2023* +123%* 2000000 • Last 3 periods : 46%, 120% and 123%* quarter over quarter growth 1500000 • 278% growth*: year ove
Slide 18: Rare Cannabinoids in Health and Wellness – Rapidly Emerging Sector
Rare Cannabinoids in Health and Wellness – Rapidly Emerging Sector CBC GROWTH TREND - SIMILAR TO OTHER MORE ESTABLISHED RARE CANNABINOIDS Sales of products containing rare Total Infused Gummies Sales in US cannabinoids – significant increase over the (Sales % Change: 4Q22 vs. 4Q21) last 3 years CBG
Slide 19: Corporate
Corporate
Slide 20: Bringing Together a Depth of Cannabinoid Expertise
Bringing Together a Depth of Cannabinoid Expertise EXTENSIVE EXPERIENCE IN PHARMA R&D, CANNABINOID/API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Michael Woudenberg, PEng Alexandra Mancini, MSc Eric Hsu, PhD Colin Clancy Chief Executive Officer Chief Operating Officer SVP, Clinical &
Slide 21: Financial Snapshot
Financial Snapshot As of 2023-07-31 Cash and Short-term Investments (As of March 31, 2023) $9.6 M Shares I/O 3.33 M Options 0.11 M Warrants and Preferred Investment Options 3.53 M Fully Diluted Shares 6.97 M Close US$1.12 52-week High US$19.50 52-week Low US$0.90 Avg. Daily Volume (Trailing 50 Days)
Slide 22: Calendar 2023 – Key Value Drivers
Calendar 2023 – Key Value Drivers • Evaluate commercial partnerships for INM-755 • Candidate selection for neurodegenerative disease program in next 2 months • Supporting revenue growth: fiscal 2023 year-end results in September • Advance glaucoma program towards human clinical trials • Target propr
Slide 23: Thank you!
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications cclancy@inmedpharma.com +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (September 2023) on 6ix